Steatohepatitis/Metabolic Liver Disease News

Patients with nonalcoholic fatty liver disease had an increased risk for dementia, with stronger risk existing for those with comorbid heart disease or stroke, according to a study published in Neurology.

In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis.

LONDON — Lower fatigue scores at baseline correlated with adverse clinical events among patients with advanced nonalcoholic steatohepatitis, according to research presented at the International Liver Congress.

LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.

LONDON — Magnetic resonance elastography in combination with the fibrosis-4 index was a better predictor of significant fibrosis in patients with nonalcoholic fatty liver disease vs. other noninvasive techniques, noted a presenter here.

LONDON — Support vector machines had the highest accuracy in predicting liver decompensation among a subset of patients in Germany compared with other machine learning models, according to data presented at the International Liver Congress.

LONDON — Nonalcoholic fatty liver disease and alcohol-associated liver disease are among the main contributors of increased mortality related to chronic liver disease and liver cancer burden, according to research.

LONDON — Elevated noninvasive markers of liver fibrosis correlated with an increased risk for cardiovascular events, end-stage renal disease and worse survival in patients with chronic kidney disease and nonalcoholic fatty liver disease.

LONDON — Patients with nonalcoholic fatty liver disease had worse health-related quality of life, regardless of fibrosis stage, compared with the general population, according to research presented at the International Liver Congress.

LONDON — Younger-onset type 2 diabetes increased the risk for liver-related events among patients with nonalcoholic fatty liver disease, according to research presented at the International Liver Congress.